The latest news, announcements and press releases from Evotec AG.
Hamburg, Germany, 26 September 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.
Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on development of advanced technologies in support thereof.
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases.
Hamburg, Germany, 12 June 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering a research payment of US$ 20 m to Evotec. A target-based programme progresses into late pre-clinical development, further contributing to the fast-growing and promising pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.
Hamburg, Germany, and New York, USA, 10 January 2024:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company has joined forces with the Crohn’s & Colitis Foundation (“the Foundation”), the leading non-profit organisation focused on both research and patient support for inflammatory bowel disease (“IBD”), which includes Crohn’s disease and ulcerative colitis.
Germany and France, 06. July 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).
Hamburg, Germany, 20 April 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® 2 EU, Evotec’s second innovative cGMP biomanufacturing facility, will employ Just – Evotec Biologics’ cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms.
J.POD® 2 EU will be Evotec’s first commercial biomanufacturing facility in Europe and is anticipated to deliver much needed capacity, flexibility and quality for biotherapeutic development and manufacturing. The construction of Evotec’s first J.POD® 1 US in Redmond, Washington is proceeding on schedule and will be fully operational in H2 2021.
With its wholly owned subsidiary, Just – Evotec Biologics, Evotec is ideally positioned to build the capacity required for the fight against COVID-19 and future pandemic threats delivering rapid, high quality outcomes. Evotec is supporting multiple projects against COVID-19, including partnerships with the Bill & Melinda Gates Foundation and the United States Department of Defense.
Hamburg, Germany, 22 March 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
Evotec and Takeda will jointly identify and develop small molecules targeting a range of RNA targets aligned with Takeda’s research and development areas. The collaboration will leverage Evotec’s extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics.
This is the News section of the company profile page for Evotec AG on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
